Objective: In the present study, we aimed to investigate the potential role of fatty acid synthase (FASN) in the development and progression of colorectal cancer (CRC). Materials and methods: FASN levels were analyzed in human CRC tissues and adjacent normal tissues by Western blots and immunohistochemistry. Potential roles of FASN in regulating CRC cell proliferation and migration were examined by genetic manipulation in vitro. The molecular signaling was determined to understand the mechanisms of observed FASN effects. Results: FASN level was upregulated in CRC tissues and high expression of FASN was significantly associated with lymph node metastasis, TNM (Tumor, Node, Metastases) stage and poor prognosis in patients with CRC. Knockdown of FASN attenuated CRC cell proliferation and migration in vitro while FASN overexpression possessed the opposite effects. FASN regulated AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) pathway in CRC cells. Conclusion: FASN enhanced CRC cell proliferation and metastasis potentially through AMPK/mTOR pathway, indicating that FASN/AMPK/mTOR signaling axis may serve as a potential target for the treatment of CRC.
Introduction
Colorectal cancer (CRC) is the third most common malignant cancer and the fourth leading cause of cancer-related death in the world. 1 In spite of emerging achievements in diagnosis and treatment of CRC, the incidence and mortality are still rampant. 2 Hence, it is essential to identify effective and specific biomarkers of CRC and develop new treatment target to halt progression of CRC. There are increasing evidence that metabolic reprogramming is a hallmark of cancer. 3, 4 Among all the metabolic changes, enhanced lipogenesis is considered as an important factor to support cancer cell unrestricted proliferation and metastasis. [5] [6] [7] As a key enzyme involved in the de novo biogenesis of fatty acids, fatty acid synthase (FASN) plays a vital role in energy homeostasis by converting excess carbon intake into fatty acids for storage. It has been reported that FASN was overexpressed in several malignant diseases, such as ovarian cancer, breast cancer, prostate cancer and gastric cancer. [8] [9] [10] [11] Besides, overex-metastasis, poor prognosis and high risk of recurrence. [12] [13] [14] Recently, there were several studies focusing on FASN in CRC, which described that FASN was overexpressed in CRC and inhibition of FASN blocked the proliferation and metastasis of CRC cells, 5, 15, 16 but the precise underlying mechanisms are equivocal and remain to be further explored.
In this study, we first detected the expression of FASN in CRC tissues and paired non-tumor tissues, and then investigated its effects on CRC cell proliferation and migration in vitro. Moreover, we also examined its effects on regulation of AMPK/mTOR pathway. Our studies demonstrate that FASN may function as a regulator for AMPK/mTOR pathway to mediate CRC cell proliferation and metastasis, which reveals a possible implication for new approaches to CRC therapy.
Materials and methods

CRC tissues and cell lines
A total of 18 pairs of primary CRC tumors and surrounding normal mucosal tissues were obtained from patients who underwent curative surgery from 2016 to 2017 at the Department of General Surgery, the First Affiliated Hospital of Soochow University (Suzhou, Jiangsu, People's Republic of China). Another 113 formalin-fixed, paraffin-embedded tissues of CRC diagnosed between 2009 and 2014 at the First Affiliated Hospital of Soochow University were enrolled. The clinicopathologic information is shown in Table 1 . Written informed consent was obtained from all patients. In addition, the study was approved by the First Affiliated Hospital of Soochow University Ethics Committee and was conducted in compliance with the Declaration of Helsinki.
CRC cell lines (SW480, HCT116, SW620, LoVo, CaCo2) and normal colon epithelial cells (NCM460) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, People's Republic of China) and were cultured in Roswell Park Memorial Institute 1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) or DMEM (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin G sodium and 100 µg/mL streptomycin sulfate (Gibco; Thermo Fisher Scientific, Inc.). All cells were maintained at 37°C in a humidified atmosphere containing 5% CO2.
Western blot assay and immunohistochemistry (IHC)
Western blot assay and IHC were described in our previous study. 17, 18 Antibodies used in this study are as follows: anti-FASN (#3180, Cell Signaling Technology (CST)), antip-AMPKα (Thr172) (#2535, CST), anti-p-mTOR (S2448) (#9205, CST), anti-AMPKα (#2532, CST), anti-mTOR (#2983, CST) and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH, #AG019, Beyotime).
Construction of stable cell lines
SW480 and HCT116 cell lines stably expressing FASNspecific short hairpin RNA (shRNA) and a plasmid encoding human FASN were generated using a lentivirus technique (GenePharma, Shanghai, People's Republic of China), as described in our previous study. 17 The human FASN shRNA target sequences are 5′-TACGACTACGGCCC-TCATT-3′.
Colony formation assay
In total, 1,000 cells were placed in 6-well plates for 7-10 days, and then fixed with 4% paraformaldehyde (Beyotime Institute of Biotechnology; Haimen, People's Republic of China) and stained with 0.1% crystal violet (Beyotime Institute of Biotechnology). Detailed protocol was described in our previous study.
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Cell migration assay
Transwell migration assay was used in this study. Detailed protocol was described in our previous study.
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Statistical analysis Figure 1A and B). We then conducted IHC to assess the level of FASN protein in 113 CRC tissues and 32 adjacent nontumorous tissues. The CRC tissues presented FASN positive staining, whereas the normal tissues showed negative staining ( Figure 1C) . The difference was statistically significant (P<0.01, Figure 1E left). Our results also revealed that FASN expression in patients with LNM was further upregulated compared with those without LNM (P<0.01, Figure 1C and E). Besides, cytologic experiments showed that there was higher FASN expression in five CRC cell lines (SW480, HCT116, SW620, LoVo, CaCo2), compared to non-CRC NCM460 cells ( Figure 1F ).
Next, we studied the relationship between FASN expression and clinicopathological parameters in 113 patients suffered from CRC. We found that the increased expression of FASN was significantly correlated with LNM (P<0.001, Table 1 ) and TNM stage (P<0.001, Table 1 ). However, there was no significant difference regarding age, gender, tumor size, tumor location or depth of invasion (P>0.05, Table 1 ).
These data suggested that FASN expression is upregulated in human CRC tissues and enhanced FASN expression is associated with the development of CRC.
High expression of FASN leads to poor prognosis
To investigate the prognostic role of FASN protein in CRC patients, we next used the Kaplan-Meier method with log- Figure 1D ), which demonstrated the prognostic value of FASN in CRC.
FASN knockdown and overexpression efficiency on CRC cells
To explore the roles of FASN in CRC cells, we used retroviral transduction to stably knockdown and overexpress FASN expression in SW480 and HCT116 cell lines. Western blot analysis was used to confirm the knockdown and overexpression efficiency. As shown in Figure 2A , Figure 2B ).
FASN promotes CRC cell proliferation and migration in vitro
Since FASN is overexpressed in CRC tissues, we then performed experiments to test the effects of FASN on CRC cell proliferation and metastasis. Colony formation assays showed that FASN knockdown resulted in the weakness of the ability to form foci in SW480 cells (P<0.01, Figure 3A) . By contrast, FASN overexpression had the opposite effect in HCT116 cells (P<0.01, Figure 3B ). Next, migration assays were conducted to assess the effects of FASN on CRC cell migration ability. Results showed that the migration ability of SW480 cells was greatly impaired when cells lacked FASN (P<0.05, Figure 3C ). In contrary, FASN overexpression significantly enhanced the migration ability in HCT116 cells (P<0.01, Figure 3D ). These results indicated that FASN enhances CRC cell proliferation and migration in vitro.
FASN regulates AMPK/mTOR pathway in CRC cells
Existing studies suggest that dysregulation of AMPK/ mTOR signaling pathway is associated with a variety of cancers including non-small cell lung cancer, 19 pancreatic cancer 20 and CRC. 21 Therefore, we sought to detect whether AMPK/mTOR pathway is implicated in the FASN-mediated CRC cell proliferation and metastasis. We found that knockdown of FASN significantly increased the level of phosphorylated AMPK (p-AMPK) in both SW480 and HCT116 cells, but not the total AMPK level (P<0.01, Figure 4A ). At the same time, the phosphorylation of mTOR (p-mTOR) was markedly decreased by FASN silencing even though the total level of mTOR was not changed (P<0.01, Figure 4A ). In contrast, overexpression of FASN led to an inhibition of AMPK phosphorylation while an increase of mTOR phosphorylation concomitantly (P<0.01, Figure 4B ). These assays revealed that FASN acts as an important regulator on AMPK/ mTOR pathway in CRC cells.
Discussion
It is widely accepted that metabolic reprogramming is considered as a hallmark of cancer and cancer cells acquire characteristic changes in metabolism to support their unrestricted proliferation and metastasis. [5] [6] [7] Among all the metabolic alterations, activation of the de novo fatty acid synthesis pathway is indispensable for carcinogenesis. 5, 22 FASN, as a key enzyme of de novo fatty acid synthesis, has been commonly found overexpressed in cancers, [8] [9] [10] [11] providing cancer cells with an extra source of cellular fatty acids. Besides, studies showed that overexpression of FASN was associated with tumor cell proliferation, metastasis, poor prognosis and high risk of recurrence. [12] [13] [14] In CRC, FASN was also shown to be highly expressed and associated with the development and progression of CRC. 5, 15, 16 However, the precise mechanisms of the regulation of cell proliferation and metastasis by FASN are not well understood and remain to be further explored.
In the present study, we provided further evidence that FASN expression was higher in CRC tissues than that in the adjacent normal tissues. Moreover, clinical data analyses showed that high expression of FASN was significantly associated with LNM, TNM stage and poor prognosis in patients with CRC. We also evidenced that silencing FASN weakened the ability of CRC cell proliferation and migration in vitro while FASN overexpression had the opposite effects, highlighting the critical role of FASN in CRC.
Considering that dysregulation of AMPK/mTOR signaling pathway is associated with variety of cancers including non-small cell lung cancer, 17 pancreatic cancer 18 and CRC, 19 we then asked whether AMPK/ mTOR pathway is implicated in the FASN-mediated CRC cell proliferation and metastasis. In accordance with the previous studies, 11, 23 which indicated the effects of FASN on AMPK in gastric cancer and ovarian cancer, we also showed that FASN modulated AMPK/mTOR pathway in CRC cells. Evidence 15 pointed out that inhibition of FASN led to a decrease of ATP production in CRC cell. ATP depletion is known to activate AMPK, which gauges the AMP and ATP levels of the cell. 24 At the same time, AMPK, as a pivotal energy sensor governing normal and cancer cell metabolism, is a major negative regulator of the mTOR pathway, which intimately relates to cell proliferation, metastasis and invasion. 25, 26 Thus, it is plausible that in CRC cells, enhanced FASN expression may increase ATP production, resulting in AMPK inhibition and mTOR activation, thus promoting CRC cell proliferation and metastasis. In summary, our present study indicated that FASN was upregulated in CRC tissues and high expression of FASN was significantly associated with LNM, TNM stage and poor prognosis in patients with CRC. We also emphasized the role of FASN in regulating CRC cell proliferation and migration in vitro. Moreover, we revealed a potential mechanism through which FASN could induce CRC cell proliferation and metastasis via its regulation of the AMPK/mTOR pathway, indicating that FASN/AMPK/ mTOR signaling axis may serve as a potential target for treatment of CRC.
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